Research & Clinical Trials Awareness Flashcards
7 cards from real AAC practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Research & Clinical Trials Awareness flashcards as text
What is 'amyloid PET imaging' used for in Alzheimer's research?
Answer: To visualize and quantify amyloid plaque deposits in the living brain
Amyloid PET scans use radioactive tracers that bind to amyloid plaques, allowing researchers to see and measure plaque burden in living participants.
What distinguishes 'disease-modifying' treatments from 'symptomatic' treatments in Alzheimer's research?
Answer: Disease-modifying treatments aim to alter the underlying disease process, while symptomatic treatments only address symptoms without changing progression
Disease-modifying therapies target the biological mechanisms driving Alzheimer's pathology, whereas symptomatic therapies temporarily improve cognition or behavior without slowing progression.
The AHEAD 3-45 Study is designed to prevent Alzheimer's by treating individuals who are:
Answer: Asymptomatic but have intermediate or elevated amyloid levels detected by PET scan
AHEAD 3-45 targets cognitively normal adults with intermediate (A3) or elevated (A45) amyloid to test lecanemab in the earliest biological stage of Alzheimer's.
What is the term for the unintended health problems that a participant might experience due to an experimental drug in a clinical trial?
Answer: Adverse events
Adverse events are any undesirable medical occurrences in a participant during a clinical trial, whether or not they are related to the investigational drug.
Which Alzheimer's research network conducts observational studies tracking cognitive decline and biomarkers in older adults across multiple U.S. sites?
Answer: Alzheimer's Disease Neuroimaging Initiative (ADNI)
ADNI is a major public-private partnership that collects standardized MRI, PET, biofluid, and cognitive data from thousands of participants to identify Alzheimer's biomarkers.
In Alzheimer's trials, ARIA (Amyloid-Related Imaging Abnormalities) is a side effect most associated with which type of therapy?
Answer: Anti-amyloid immunotherapy drugs such as lecanemab or aducanumab
ARIA — characterized by brain swelling (ARIA-E) or microhemorrhages (ARIA-H) — is a known risk associated with anti-amyloid antibody therapies and requires MRI monitoring.
What is the purpose of a 'Data Safety Monitoring Board' (DSMB) in an Alzheimer's clinical trial?
Answer: To independently review accumulating safety and efficacy data and recommend stopping or continuing the trial
A DSMB is an independent expert committee that monitors unblinded data during a trial to protect participant safety and ensure the trial is still scientifically valid.